Non-immunogenic staphylokinase in patients with massive intermediate-high risk pulmonary embolism: protocol of the FORPE-2 multicenter, double-blind, randomized, placebo-controlled trial

Non-immunogenic staphylokinase in patients with massive intermediate-high risk pulmonary embolism: protocol of the FORPE-2 multicenter, double-blind, randomized, placebo-controlled trial

Aim. To evaluate the efficacy and safety of single bolus administration of non-immunogenic staphylokinase in comparison with placebo in patients with intermediatehigh risk pulmonary embolism (PE) within the FORPE-2 clinical trial.Material and methods. Non-immunogenic staphylokinase has high thrombol...

Full description

Saved in:
Bibliographic Details
Main Authors: S. N. Tereshchenko, E. B. Yarovaya, S. G. Leontiev, I. S. Yavelov, R. M. Shakhnovich, A. D. Erlikh, T. M. Uskach, D. V. Duplyakov, V. A. Kutsenko, O. E. Ivlev, A. G. Soplenkova, A. M. Semenov, M. P. Semenov, S. V. Ivanov, S. S. Markin
Format: Article
Language:Russian
Published: «FIRMA «SILICEA» LLC 2025-03-01
Series:Российский кардиологический журнал
Subjects:
intermediate-high risk pulmonary embolism
thrombolysis
non-immunogenic staphylokinase
Online Access:https://russjcardiol.elpub.ru/jour/article/view/6291
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://russjcardiol.elpub.ru/jour/article/view/6291

Similar Items